Kairos Pharma, LTD. — Director's Dealing 2024

Nov 26, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2024-11-25

Reporting Person: Murali Ramachandran (VP of Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-25	COMMON STOCK	P	200	$1.59	Acquired	133057	Direct